Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Fresh Guidelines Issued For Cervical Cancer Screening

By LabMedica International staff writers
Posted on 27 Mar 2012
Women ages 21 to 65 should have a Babeş-Papanicolaou test, commonly known as a Pap smear, every three years, according to new guidelines.

Based on the evidence, women between the ages of 30 and 65 can safely extend the screening interval to once every five years if they undergo the human papillomavirus (HPV) test at the same time as the Pap smear. More...


The United States Preventive Services Task Force (USPSTF; Agency for Healthcare Research and Quality, Rockville, MD, USA) has reviewed new evidence on the comparative test performance of liquid-based cytology and the benefits and harms of HPV testing as a stand-alone test or in combination with cytology. Screening with cervical cytology or testing for multiple oncogenic HPV types (a test for the presence of greater than two high-risk or carcinogenic HPV types, called HPV testing) can lead to detection of high-grade precancerous cervical lesions and cervical cancer.

The effectiveness of cervical cancer screening observed in the US over the past several decades is attributed to the use of conventional cytology. Current evidence indicates that there are no clinically important differences between liquid-based cytology and conventional cytology. HPV testing with Digene Hybrid Capture 2 (HC2) (Qiagen; Germantown, MD, USA) is commonly used in the US, and both HC2 and polymerase chain reaction–based methods have been evaluated in effectiveness trials. Although alternative HPV detection methods are emerging, the clinical comparability and implications of these methods are not completely understood.

According to the Task Force guidelines, women who have had a hysterectomy with removal of the cervix and who do not have a history of cervical cancer or a high-grade precancerous lesion do not need to be screened. In this population, there is high certainty that harms of screening outweigh the benefits. Women over the age of 65 can end screening if they have had three consecutive negative Pap smears or two consecutive negative co-tests within 10 years before cessation of screening, with the last test occurring within five years. Routine screening should continue at least 20 years after spontaneous regression or appropriate management of high-grade precancerous lesion, regardless of the patient's age.

Virginia Moyer, MD, MPH, professor of pediatrics at Baylor Medical College (Houston, TX, USA), said, "This is good news for women because evidence shows that an annual Pap smear is not necessary to prevent deaths from cervical cancer. Screening every three years starting at age 21 saves the same number of lives as annual screening, but with half the number of colposcopies and fewer false-positive tests.” The guidelines were published on March 15, 2012, in the journal Annals of Internal Medicine.

Related Links:

United States Preventive Services Task Force
Qiagen
Baylor Medical College



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.